Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas

Human epidermal growth factor receptor 2 (HER2) has been evaluated in breast cancer patients to identify those most likely to benefit from herceptin-targeted therapy. HER2 amplification, detected in 20-30% of invasive breast tumors, is associated with reduced survival and metastasis. The most freque...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosa, F.E., Santos, R.M., Rogatto, S.R., Domingues, M.A.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Divulgação Científica 2013
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854374/
https://www.ncbi.nlm.nih.gov/pubmed/23558859
http://dx.doi.org/10.1590/1414-431X20132483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854374/
https://www.ncbi.nlm.nih.gov/pubmed/23558859
http://dx.doi.org/10.1590/1414-431X20132483

Ejemplares similares